BioSpace News Archive

Applied Genetic Technologies Corporation, a biotechnology company conducting human clinical trials of adeno-associated virus -based gene therapies for the treatment of rare retinal diseases, reported 12-month data from its ongoing achromatopsia Phase 1/2 clinical trials, including data from all adult patients and low-dose pediatric patients.

Encouraging Pharmacokinetics, Pharmacodynamics and Safety Profile at 15mg/kg of AVB-500

Aileron Therapeutics, a chemoprotection oncology company focused on fundamentally transforming the experience of chemotherapy for cancer patients, announced that it is set to join the Russell Microcap® Index at the conclusion of the 2021 Russell indexes annual reconstitution, effective after the U.S. market opens on June 28, 2021.

Werewolf Therapeutics, Inc., an innovative biopharmaceutical company pioneering the development of conditionally activated therapeutics engineered to stimulate the body’s immune system for the treatment of cancer, announced that it will be added to the Russell 2000® Index at the conclusion of the Russell US Indexes annual reconstitution on June 28, 2021.

Shenzhen Chipscreen Biosciences’ licensing partner, HUYABIO International, announced the regulatory approval for Tucidinostat monotherapy of relapsed or refractory adult T-cell leukemia/lymphoma by the Japanese Pharmaceuticals and Medical Devices Agency.

Boston Scientific Corporation announced it exercised its option to acquire the remaining shares of Farapulse, Inc.

Alnylam Pharmaceuticals, Inc., the leading RNAi therapeutics company, announced that the U.S. Food and Drug Administration has accepted the Company’s New Drug Application for vutrisiran, an investigational RNAi therapeutic for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults.

Navidea Biopharmaceuticals, Inc. , today announced that on June 23, 2021, Vice Chancellor Joseph Slights of the Court of Chancery of the State of Delaware (the “Court”) ruled in favor of Navidea’s wholly-owned subsidiary, Macrophage Therapeutics, Inc.

Santen Inc., the U.S. subsidiary of Santen Pharmaceutical Co., Ltd., a global company focused exclusively on eye care, announced that the U.S. Food and Drug Administration has approved Verkazia™ 0.1% eye drops for the treatment of vernal keratoconjunctivitis in children and adults.

Foundation Medicine, Inc. and its collaborators announced results from a Dana-Farber Cancer Institute-led study that used genomic testing, including Foundation Medicine’s liquid-based comprehensive genomic profiling test, FoundationOne®Liquid CDx, among several assays, to investigate resistance mechanisms in 38 patients with cancer treated with a KRAS G12C inhibitor.